A
Asgard Therapeutics
Biotech & Life Sciences · Lund Municipality, Sweden · Founded 2018
Spin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming MoreLess
Asgard Therapeutics is a Swedish biotech startup focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company is pioneering gene therapy approaches, with its flagship program, AT108, designed to trigger immune responses by leveraging the biological properties of professional antigen-presenting cells. This method aims to simplify the logistics and manufacturing challenges associated with traditional cell-based therapies, making it a more accessible "off-the-shelf" solution.
Asgard Therapeutics primarily serves the healthcare and pharmaceutical sectors, targeting patients and medical professionals in need of advanced cancer treatments. The company operates in the highly specialized biotech market, which is characterized by rapid innovation and significant investment in research and development.
The business model of Asgard Therapeutics revolves around the development and commercialization of its proprietary gene therapy solutions. The company generates revenue through various channels, including grants, venture capital investments, and potential future sales of its therapies. Notably, it has received support from prominent entities such as the Bio Innovation Institute and the Boehringer Ingelheim Venture Fund, which invest in groundbreaking therapeutic-focused biotechnology companies.
In summary, Asgard Therapeutics is at the forefront of cancer immunotherapy innovation, leveraging cutting-edge gene therapy techniques to create more effective and accessible treatments. The company’s strategic partnerships and funding support underscore its potential to make significant advancements in patient care.
Keywords: Cancer Immunotherapy, Gene Therapy, Biotech, Cell Reprogramming, Healthcare, Pharmaceutical, Innovation, Research, Venture Capital, Sweden.
Company overview
Asgard Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Lund Municipality, Sweden
- Employees
- 28
- Open positions
- 1
- Dealroom signal
- 71.2
Valuation & funding
Asgard Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2024 | $33M | $132M | Novo Holdings · Boehringer Ingelheim Venture Fund · Industrifonden · Johnson & Johnson Innovation | ↗ |
| SEED✓Equity / VC | Nov 2021 | $6.6M | $26M | Novo Holdings · Novo Seeds · Industrifonden · Boehringer Ingelheim Venture Fund | ↗ |
| OtherOther financing | Sep 2020 | $0 | — | LU Innovation | ↗ |
| SPINOUT✓Other financing | Jan 2018 | $0 | — | Lund University | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | Profit | Margin |
|---|---|---|---|---|
| 2026 | $862K | 0% | −$7.9M | -918.6% |
| 2025 | $862K | 0% | −$7.9M | -918.6% |
| 2024 | $862K | +148.9% | −$7.9M | -918.6% |
| 2023 | $346K | -4.8% | ||
| 2022 | $364K | +666.3% | ||
| 2021 | $47K | 0% | ||
| 2020 | $47K | — |
Growth signals
Asgard Therapeutics website traffic
Latest recorded traffic for Asgard Therapeutics is 5.1K monthly website visits, up 4.1% over the last three months. Asgard Therapeutics's team grew 3.7% over the past year.
Comparisons
Asgard Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Asgard Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Asgard Therapeutics has talent and traffic
team presence
In the news
Latest news about Asgard Therapeutics
Recent press, funding announcements, and product moves mentioning Asgard Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Asgard Therapeutics
An AI-synthesized read of the highest-engagement posts about Asgard Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Asgard Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.